Cancer Protein CA125 Blocks Investigational Therapy Farletuzumab’s Anti-Tumor Effectiveness, Study Finds

Cancer Protein CA125 Blocks Investigational Therapy Farletuzumab’s Anti-Tumor Effectiveness, Study Finds
The protein CA125, which is commonly expressed on the surface of ovarian cancer cells and is secreted into the bloodstream, was found to block the activity of investigational drug farletuzumab. Farletuzumab is currently in clinical development for the treatment of ovarian cancer. This process was described in the preclinical study, “Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC)

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *